Rheumatoid Arthritis and other Inflammatory Joint Pathologies

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 843-869

  Goldring, Steven R ^a   Goldring, Mary B ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42549164669     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50052-2     Document Type: Chapter

References (374)

1. Goldring S.R., Goldring M.B. Biology of the normal joint. Kelley's Textbook of Rheumatology 2004, 1-34. WB Saunders, Philadelphia, PA. E.D. Harris, S. Ruddy, C.B. Sledge, J.S. Sergent, R.C. Budd (Eds.).
2. Tak P.P., Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000, 43:2619-2633.
3. Yamanishi Y., Firestein G.S. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. North Am. 2001, 27:355-371.
4. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
5. Harris E.D. Kelley's Textbook of Rheumatology 2004, WB Saunders, Philadelphia, PA. E.D. Harris, S. Ruddy, C.B. Sledge, J.S. Sergent, R.C. Budd (Eds.).
6. Fassbender H.G. Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Coll. Rel. Dis. 1983, 3:141-155.
7. Krane S.M., Conca W., Stephenson M.L., Amento E.P., Goldring M.B. Mechanisms of matrix degradation in rheumatoid arthritis. Ann. NY Acad. Sci. 1990, 580:340-354.
8. Harris E.D.J. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 1990, 322:1277-1289.
9. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344:907-916.
10. Corrigall V.M., Panayi G.S. Autoantigens and immune pathways in rheumatoid arthritis. Crit. Rev. Immunol. 2002, 22:281-293.
11. Combe B., Dougados M., Goupille P., Cantagrel A., Eliaou J.F., Sibilia J., Meyer O., Sany J., Daures J.P., Dubois A. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 2001, 44:1736-1743.
12. Jansen L.M., van der Horst-Bruinsma I.E., van Schaardenburg D., Bezemer P.D., Dijkmans B.A. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 2001, 60:924-927.
13. van der Heijde D.M., van Riel P.L., van Leeuwen M.A., van't Hof M.A., van Rijswijk M.H., van de Putte L.B. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br. J. Rheumatol. 1992, 31:519-525.
14. Mottonen T., Paimela L., Leirisalo-Repo M., Kautiainen H., Ilonen J., Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann. Rheum. Dis. 1998, 57:533-539.
15. Goronzy J.J., Matteson E.L., Fulbright J.W., Warrington K.J., Chang-Miller A., Hunder G.G., Mason T.G., Nelson A.M., Valente R.M., Crowson C.S., Erlich H.A., Reynolds R.L., Swee R.G., O'Fallon W.M., Weyand C.M. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum. 2004, 50:43-54.
16. Mulherin D., Fitzgerald O., Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br. J. Rheumatol. 1996, 35:1263-1268.
17. Kirwan J., Byron M., Watt I. The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:297-301.
18. van den Berg W.B. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin. Arthritis Rheum. 2001, 30:7-16.
19. Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand. J. Rheumatol. Suppl. 2004, 1-38.
20. Garnero P., Rousseau J.C., Delmas P.D. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 2000, 43:953-968.
21. Garnero P., Geusens P., Landewe R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin. Exp. Rheumatol. 2003, 21:S54-S58.
22. Garnero P., Delmas P.D. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr. Opin. Rheumatol. 2004, 16:428-434.
23. Mansson B., Carey D., Alini M., Ionescu M., Rosenberg L.C., Poole A.R., Heinegard D., Saxne T. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J. Clin. Invest. 1995, 95:1071-1077.
24. Poole A.R., Ionescu M., Swan A., Dieppe P.A. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J. Clin. Invest. 1994, 94:25-33.
25. Gamero P., Landewe R., Boers M., Verhoeven A., Van Der Linden S., Christgau S., Van der Heijde D., Boonen A., Geusens P. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum. 2002, 46:2847-2856.
26. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., Rosenquist C., Qvist P. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
27. Kojima T., Mwale F., Yasuda T., Girard C., Poole A.R., Laverty S. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum. 2001, 44:120-127.
28. Fraser A., Fearon U., Billinghurst R.C., Ionescu M., Reece R., Barwick T., Emery P., Poole A.R., Veale D.J. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003, 48:3085-3095.
29. Lindqvist E., Eberhardt K., Bendtzen K., Heinegard D., Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64:196-201.
30. Deodhar A.A., Woolf A.D. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br. J. Rheumatol. 1996, 35:309-322.
31. Goldring S.R. Osteoporosis and rheumatic diseases. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metablism 1996, 299-301. Lippincott-Raven, Philadelphia, PA. 3rd Edition. M.J. Favus (Ed.).
32. Goldring S.R., Polisson R.P. Bone disease in rheumatological disorders. Metabolic Bone Disease 1998, 621-635. Academic Press, San Diego, CA. 2nd Edition. L. Avioli, S.M. Krane (Eds.).
33. Bromley M., Woolley D.E. Chondroclasts and osteoclasts at subchondral sites of erosions in the rheumatoid joint. Arthritis Rheum. 1984, 27:968-975.
34. Bromley M., Woolley D.E. Histopathology of the rheumatoid lesion; identification of cell types at sites of cartilage erosion. Arthritis Rheum. 1984, 27:857-863.
35. Allard S.A., Muirden K.D., Maini R.N. Correlation of histopathological features of pannus with patterns of damage in different joints in rheumatoid arthritis. Ann. Rhenum. Dis. 1991, 50:278-283.
36. Ashton B.A., Ashton I.K., Marshall M.J., Butler R.C. Localization of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory and degenrative arthritis. Ann. Rheum. Dis. 1993, 52:133-137.
37. Chang J.S., Quinn J.M., Demaziere A., Bulstrode C.J., Francis M.J., Duthie R.B., Athanasou N.A. Bone resorption by cells isolated from rheumatoid synovium. Ann. Rheum. Dis. 1992, 51:1223-1229.
38. Chambers T.J., Thomson B.M., Fuller K. Resorption of bone by isolated rabbit osteoclasts. J. Cell. Sci. 1984, 66:383.
39. Hummel K.M., Petrow P.K., Franz J.K., Muller-Ladner U., Aicher W.K., Gay R.E., Bromme D., Gay S. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J. Rheumatol. 1998, 25:1887-1894.
40. Hattersley G., Chambers T.J. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology 1989, 125:1606-1612.
41. Fujikawa Y., Sabokbar A., Neale S., Athanasou N.A. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann. Rheum. Dis. 1993, 55:816-822.
42. Itonaga I., Fujikawa Y., Sabokbar A., Murray D.W., Athanasou N.A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J. Pathol. 2000, 192:97-104.
43. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., Tanaka S. Involvement of receptor activator of nuclear factor ?B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000, 43:259-269.
44. Haynes D.R., Crotti T.N., Loric M., Bain G.I., Atkins G.J., Findlay D.M. Osteoprotegerin and receptor activator of nuclear factor ?B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001, 40:623-630.
45. Suzuki Y., Tsutsumi Y., Nakagawa M., Suzuki H., Matsushita K., Beppu M., Aoki H., Ichikawa Y., Mizushima Y. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 2001, 40:673-682.
46. Gravallese E.M., Harada Y., Wang J.-T., Gorn A., Thornhill T., Goldring S.R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 1998, 152:943-951.
47. Gorn A.H., Lin H.Y., Yamin M., Auron P.E., Flannery M.R., Tapp D.R., Manning C.A., Lodish H.F., Krane S.M., Goldring S.R. The cloning, characterization and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J. Clin. Invest. 1992, 90:1726-1735.
48. Gorn A.H., Rudolph S.M., Flannery M.R., Morton C., Weremowicz S., Wang J.-T., Krane S.M., Goldring S.R. Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. J. Clin. Invest. 1995, 95:2680-2691.
49. Lee S.K., Goldring S.R., Lorenzo J.A. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology 1995, 136:4572-4581.
50. Rodan G.A., Martin T.J. Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif. Tissue Int. 1981, 33:349-351.
51. Raisz L.G. Local and systemic factors in the pathogenesis of osteoporosis. N. Engl. J. Med. 1988, 318:818-828.
52. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr. Rev. 1992, 13:66-80.
53. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., Benoist C., Gravallese E.M. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001, 159:1689-1699.
54. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., Penninger J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
55. Korganow A., Weber J.C., Martin T. Animal models and autoimmune diseases. Rev. Med. Interne. 1999, 20:283-286.
56. Matsumoto I., Staub A., Benoist C., Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999, 286:1732-1735.
57. Matsumoto I., Maccioni M., Lee D.M., Maurice M., Simmons B., Brenner M., Mathis D., Benoist C. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat. Immunol. 2002, 3:360-365.
58. Redlich K., Hayer S., Ricci R., David J., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J., Wagner E., Schett G. Osteoclasts are essential for TNF-?-mediated joint destruction. J. Clin. Invest. 2002, 110:1419-1427.
59. Teitelbaum S. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
60. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., Wagner E.F. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
61. Gravallese E.M., Goldring S.R. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000, 43:2143-2151.
62. Feldmann M., Maini R.N. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology 1999, 38:3-7.
63. Funk J.L., Cordaro L.A., Wei H., Benjamin J.B., Yocum D.E. Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis: a possible role for locally produced parathyroid hormone-related protein in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 1998, 101:1362-1371.
64. Chabaud M., Lubberts E., Joosten L., van Den Berg W., Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 2001, 3:168-177.
65. Ogata Y., Kukita A., Kukita T., Komine M., Miyahara A., Miyazaki S., Kohashi O. A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J. Immunol. 1999, 162:2754-2760.
66. Okano K., Tsukazaki T., Ohtsuru A., Namba H., Osaki M., Iwasaki K., Yamashita S. Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis. Br. J. Rheumatol. 1996, 35:1056-1062.
67. Romas E., Martin T.J. Cytokines in the pathogenesis of osteoporosis. Osteoporos. Int. 1997, 7:S47-S53.
68. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 1999, 265:144-150.
69. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 1997, 186:2075-2080.
70. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272:25190-25194.
71. Josien R., Wong B.R., Li H.L., Steinman R.M., Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 1999, 162:2562-2568.
72. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
73. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
74. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
75. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
76. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silveman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
77. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
78. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NF?B ligand and tumor necrosis factor-? in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
79. Redlich K., Hayer S., Maier A., Dunstan C., Tohidast-Akrad M., Lang S., Turk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., Smolen J., Schett G. Tumor necrosis factor-?-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002, 46:785-792.
80. Weitzmann M.N., Cenci S., Rifas L., Brown C., Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble oste oclastogenic cytokines. Blood 2000, 96:1873-1878.
81. Weitzmann M.N., Cenci S., Rifas L., Haug J., Dipersio J., Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor ?B ligand-dependent and-independent mechanisms. J. Bone Miner. Res. 2001, 16:328-337.
82. Kotake S., Udagawa N., Mogi M., Yano K., Tsuda E., Takahashi K., Furuya T., Ishiyama S., Kim K.J., Saito S., Nishikawa T., Takahashi N., Togari A., Tomatsu T., Suda T., Kamatani N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis. Arthritis Rheum. 2001, 44:1003-1012.
83. Stewart A., Mackenzie L.M., Black A.J., Reid D.M. Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radio grammetry: a pilot study. Rheumatology (Oxford) 2004, 43:1561-1564.
84. Shimizo S., Shiozawa S., Shiozawa K., Imura S., Fugita T. Quantitative histological studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum. 1985, 28:25-31.
85. Deleuran B.W., Chu C.Q., Field M., Brennan F.M., Katsikis P.M.F., Maini R.N. Localization of interleukin-1?, type 1 interleukin-1 receptor and interleukin-1 receptor antagonis in the synovial membrane and cartilage/pannus junction in rhumatoid arthritis. Br. J. Rheumatol. 1992, 31:801-809.
86. Firestein G.S., Alcaro-Garcia J.M., Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 1990, 144:3347-3353.
87. Chu C.Q., Field M., Feldman M., Maini R.N. Localization of tumour necrosis factor-a in synovial tissue and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34:1125-1132.
88. Chu C.Q.M.F., Allard S., Abney E., Feldmann M., Maini R.N. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis; implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 1992, 32:653-661.
89. Mazess R.B., Whedon G.D. Immobilization and bone. Calcif. Tiss. Int. 1983, 32:265.
90. Joffe I., Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin. Arthritis Rheum. 1991, 20:256-272.
91. Spector T.D., Hall G.M., McCloskey E.V., Kanis J.A. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993, 306:558.
92. Gough A.K., Lilley J., Eyre S., Holdin R., Emery P. Generalized bone loss in patients with rheumatoid arthritis. Lancet 1994, 344:23-27.
93. Hooyman J.R., Melton L.J., Nelson A.M., O'Fallon W.M., Riggs B.L. Fractures after rheumatoid arthritis: a population based study. Arthritis Rheum. 1984, 27:1353-1361.
94. Beat A.M., Bloch D.A., Fries J.F. Predictors of fractures in early rheumatoid arthritis. J. Rheumatol. 1991, 18:804-808.
95. Haugeberg G., Orstavik R.E., Kvien T.K. Effects of rheumatoid arthritis on bone. Curr. Opin. Rheumatol. 2003, 15:469-475.
96. Forslind K., Keller C., Svensson B., Hafstrom I. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J. Rheumatol. 2003, 30:2590-2596.
97. Orstavik R.E., Haugeberg G., Mowinckel P., Hoiseth A., Uhlig T., Falch J.A., Halse J.I., McCloskey E., Kvien T.K. Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch. Intern. Med. 2004, 164:420-425.
98. Orstavik R.E., Haugeberg G., Uhlig T., Mowinckel P., Falch J.A., Halse J.I., Kvien T.K. Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry. Osteoporos. Int. 2005, 16:35-42.
99. Lodder M.C., de Jong Z., Kostense P.J., Molenaar E.T., Staal K., Voskuyl A.E., Hazes J.M., Dijkmans B.A., Lems W.F. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann. Rheum. Dis. 2004, 63:1576-1580.
100. Lane N.E., Goldring S.R. Bone loss in rheumatoid arthritis: what role does inflammation play. J. Rheumatol. 1998, 7:1251-1253.
101. Sambrook P., Ansel B., Foster S., et al. Bone turnover in early rheumatoid arthritis; longitudinal bone density studies. Ann. Rheum. Dis. 1985, 44:580.
102. Sambrook P., Eisman J., Yeates M., et al. Osteoporosis in rheumatoid arthritis: safety of low-dose corticosteroids. Ann. Rheum. Dis. 1986, 45:950.
103. Sambrook P.N., Eisman A., Champion G., Yeates M.G., Pocock N.A., Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum. 1987, 30:721-728.
104. Sambrook P., Birmingham J., Kelly P., Kempler S., Freund J., Eisman J. Postmenopausal bone loss in rheumatoid arthritis: effects of estrogens and androgens. J. Rheum. 1992, 19:357-361.
105. Peel N.F., Eastell R., Russell R.G.G. Osteoporosis in rheumatoid arthritis-the laboratory perspective. Br. J. Rheum. 1991, 30:84-85.
106. Woolf A.D. Osteoporosis in rheumatoid arthritis-the clinical viewpoint. Br. J. Rheum. 1991, 30:82-84.
107. Compston J.E., Vedi S., Croucher P.I., Garrahan N.J., O'Sullivan M.M. Bone turnover in non-steroid treated rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:163-166.
108. Sambrook P., Spector T., Seeman E., Bellamy N., Russel R.D.D.N.M., Prince R., Owen E., Silman A., Eisman J. Osteoporosis in rheumatoid arthritis: a monozygotic co-twin control study. Arthritis Rheum. 1995, 38:806-809.
109. Laan R.F., Van-Riel P.L., van-de-Putte L.B. Bone mass in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1992, 51:826-832.
110. Als O.S., Gotfredsen A., Riis B.J., Christiansen C. Are disease duration and degree of functional impairment determinanats of bone loss in rheumatoid arthritis?. Ann. Rheum. Dis. 1985, 44:406-411.
111. Kroger H., Arnala I., Alhava E.M. Bone remodeling in osteoporosis associated with rheumatoid arthritis. Calcif. Tiss. Int. 1991, 49:S90.
112. Mellish R.W.E., O'Sullivan M.M., Garrahan N.J., Compston J.E. Iliac crest trabecular bone mass and structure in patients with non-steroid treated rheumatoid arthritis. Ann. Rheum. Dis. 1987, 46:830-836.
113. Hall G.M., Spector T.D., Delmas P.D. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis Rheum. 1995, 38:902-906.
114. Gough A.K., Peel N.F., Eastell R., Holder R.L., Lilley J., Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:14-17.
115. Gamero P., Gineyts E., Christgau S., Finck B., Delmas P.D. Association of baseline levels of urinary glucosyl-galactosylpyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum. 2002, 46:21-30.
116. Iwamoto J., Takeda T., Ichimura S. Urinary cross-linked N-telopeptides of type I collagen levels in patients with rheumatoid arthritis. Calcif. Tissue Int. 2003, 72:491-497.
117. Gough A., Sambrook P., Devlin J., Huissoon A., Njeh C., Robbins S., Nguyen T., Emery P. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J. Rheumatol. 1998, 7:1282-1289.
118. Black D., Marabani M., Sturrock R.D., Robins S.P. Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1989, 48:641-644.
119. Robins S.P., Stewart P., Astbury C., Bird H.A. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. Ann. Rheum. Dis. 1986, 45:969-973.
120. Siebel M.J., Duncan A., Robins S.P. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritis disease. J. Rheumatol. 1989, 16:964-970.
121. Sinigaglia L., Varenna M., Binelli L., Bartucci F., Arrigoni M., Ferrara R., Abbiati G. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 1995, 54:144-147.
122. Garnero P., Jouvenne P., Buchs N., Delmas P.D., Miossec P. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type 1 collagen breakdown products. Bone 1999, 24:381-385.
123. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., Thamsborg G., Liberman U.A., Delmas P.D., Malice P., Czachur M., Daifotis A.G. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 1998, 339:292-299.
124. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., Schwarz E.M. Mechanisms of TNF-?- and RANKL-mediated osteoclastogenesis, and bone resorption in psoriatic arthritis. J. Clin. Invest. 2003, 111:821-831.
125. McGonagle D., Benjamin M., Marzo-Ortega H., Emery P. Advances in the understanding of entheseal inflammation. Curr. Rheumatol. Rep. 2002, 4:500-506.
126. Benjamin M., McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J. Anat. 2001, 199:503-526.
127. Benjamin M., Moriggl B., Brenner E., Emery P., McGonagle D., Redman S. The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum. 2004, 50:3306-3313.
128. McGonagle D. Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann. Rheum. Dis. 2005, 64(Suppl 2):ii58-ii60.
129. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995, 4:499-505.
130. Lories R.J., Derese I., Ceuppens J.L., Luyten F.P. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003, 48:2807-2818.
131. Franck H., Ittel T. Serum osteocalcin levels in patients with psoriatic arthritis: an extended report. Rheumatol. Int. 2000, 19:161-164.
132. Spencer D., Park W., Dick H., et al. Radiologic manifestations in 200 patients with ankylosing spondylitis; correlations with clinical features and HLA-B27. J. Rheumatol. 1979, 6:305.
133. Will R., Bhalla A., Palmer R., Ring F., Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event?. Lancet 1989, 23:1483-1485.
134. Frediani B., Allegri A., Falsetti P., Storri L., Bisogno S., Baldi F., Filipponi P., Marcolongo R. Bone mineral density in patients with psoriatic arthritis. J. Rheumatol. 2001, 28:138-143.
135. Ralston S.H., Urquhart G.D., Brzeski M., Sturrock R.D. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 1990, 300:563-565.
136. Devogelaer J.-P., Maldague B., Malghem J., de Deuxchaisnes C.N. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison, of plain radiographs with single-and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum. 1992, 35:1062-1067.
137. Marzo-Ortega H., McGonagle D., Haugeberg G., Green M.J., Stewart S.P., Emery P. Bone mineraldensity improvement in spondyloarthropathy after treatment with etanercept. Ann. Rheum. Dis. 2003, 62:1020-1021.
138. Ansell B.M., Bywaters E.G.L. Growth in Still's Disease. Ann. Rheum. Dis. 1956, 15:295-318.
139. Bernstein B.H., Stobie D., Singsen B.H., Koster-King K., Kornreich H.K., Hanson V. Growth retardation in juvenile rheumatoid arthritis (JRA). Arthritis Rheum. 1977, 20:212-216.
140. Hillman L., Cassidy J.T., Johnson L., Lee D., Allen S. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J. Pediatr. 1994, 124:910-916.
141. Falcini F., Ermini M., Bagnoli F. Bone turnover is reduced in children with juvenile rheumatoid arthritis. J. Endocrinol. Invest. 1998, 21:31-36.
142. Hopp R., Degan J.A., Gallagher J.C., Cassidy J.T. Estimation of bone mineral density in children with juvenile rheumatoid arthritis. J. Rheumatol. 1991, 18:1235-1239.
143. Henderson C.J., Specker B.L., Sierra R.I., Campaigne B.N., Lovell D.J. Total-body bone mineral content in noncorticosteroid-treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum. 2000, 43:531-540.
144. Rabinovich C.E. Bone mineral status in juvenile rheumatoid arthritis. J. Rheumatol. Suppl. 2000, 58:34-37.
145. French A.R., Mason T., Nelson A.M., Crowson C.S., O'Fallon W.M., Khosla S., Gabriel S.E. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J. Rheumatol. 2002, 29:1065-1070.
146. Reed A., Haugen M., Pachman L., Langman C. Repair of osteopenia in children with juvenile rheumatoid arthritis. J. Pediatr. 1993, 122:693-696.
147. Badley B.W.D., Ansell B.M. Fracture's in Still's disease. Ann. Rheum. Dis. 1960, 19:135-138.
148. Varonos S., Ansell B.M., Reeve J. Vertebral collapse in juvenile chronic arthritis; its relationship with glucocorticoid therapy. Calcif. Tiss. Int. 1987, 41:75-78.
149. Reeve J., Loftus J., Hesp R., Ansell B.M., Wright D.J., Woo P.M. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid), arthritis treated with glucocorticoids. J. Rheum. 1993, 20:1189-1195.
150. Poole A.R., Kojima T., Yasuda T., Mwale F., Kobayashi M., Laverty S. Composition and structure of articular cartilage: a template for tissue repair. Clin. Orthop. 2001, S26-S33.
151. Poole A.R. Cartilage in health and disease. Arthritis and Allied Conditions: a Textbook of Rheumatology 2001, 226-284. Lippincott Williams & Wilkins, Philadelphia, PA. W. Koopman (Ed.).
152. Verzijl N., DeGroot J., Thorpe S.R., Bank R.A., Shaw J.N., Lyons T.J., Bijlsma J.W., Lafeber F.P., Baynes J.W., TeKoppele J.M. Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 2000, 275:39027-39031.
153. Maroudas A., Bayliss M.T., Uchitel-Kaushansky N., Schneiderman R., Gilav E. Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Arch. Biochem. Biophys. 1998, 350:61-71.
154. Kobayashi I., Ziff M. Electron microscopic studies of the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum. 1975, 18:475-483.
155. Woolley D.E., Crossley M.J., Evanson J.M. Collagenase at sites of cartilage erosion in the rheumatoid joint. Arthritis Rheum 1977, 20:1231-1239.
156. Mitchell N.S., Shepard N. Changes in proteoglycan and collagen in cartilage in rheumatoid arthritis. J. Bone Joint Surg. 1978, 60A:349-354.
157. Dodge G.R., Pidoux I., Poole A.R. The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study. Matrix 1991, 11:330-338.
158. Edwards J.C.W. Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res. 2000, 2:344-347.
159. Zvaifler N.J., Tsai V., Alsalameh S., von Kempis J., Firestein G.S., Lotz M. Pannocytes: distinctive cells found in rheumatoid arthritis articular cartilage erosions. Am. J. Pathol. 1997, 150:1125-1138.
160. Zvaifler N.J., Firestein G.S. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum. 1994, 37:783-789.
161. Muller-Ladner U., Kriegsmann J., Franklin B.N., Matsumoto S., Geiler T., Gay R.E., Gay S. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafied into SCID mice. Am. J. Pathol. 1996, 149:1607-1615.
162. Kimura H., Tateishi H.J., Ziff M. Surface ultrastructure of rheumatoid articular cartilage. Arthritis Rheum. 1977, 20:1085-1098.
163. Dodge G.R., Poole A.R. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J. Clin. Invest. 1989, 83:647-661.
164. Hembry R.M., Bagga M.R., Reynolds J.J., Hamblen D.L. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo-and rheumatoid arthritis. Ann. Rheum. Dis. 1995, 54:25-32.
165. Walakovits L.A., Moore V.L., Bhardwaj N., Gallick G.S., Lark M.W. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum. 1992, 35:35-42.
166. Clark I.M., Powell L.K., Ramsey S., Hazleman B.L., Cawston T.E. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1993, 36:372-379.
167. Ahrens D., Koch A.E., Pope R.M., Stein-Picarella M., Niedbala M.J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 1996, 39:1576-1587.
168. Ishiguro N., Ito T., Obata K., Fujimoto N., Iwata H. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J. Rheumatol. 1996, 23:1599-1604.
169. Taylor D.J., Cheung N.T., Dawes P.T. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann. Rheum. Dis. 1994, 53:768-772.
170. Manicourt D.H., Fujimoto N., Obata K., Thonar E.J. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation [see comments]. Arthritis Rheum. 1995, 38:1031-1039.
171. Yoshihara Y., Obata K., Fujimoto N., Yamashita K., Hayakawa T., Shinmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:969-975.
172. Tetlow L.C., Woolley D.E. Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro. B. J. Rheumatol. 1998, 37:64-70.
173. Cunnane G., Fitzgerald O., Beeton C., Cawston T.E., Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3 and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum. 2001, 44:2263-2274.
174. Cunnane G., FitzGerald O., Hummel K.M., Youssef P.P., Gay R.E., Gay S., Bresnihan B. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum. 2001, 44:1744-1753.
175. Maeda S., Sawai T., Uzuki M., Takahashi Y., Omoto H., Seki M., Sakurai M. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1995, 54:970-975.
176. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 2000, 59:455-461.
177. Goldbach-Mansky R., Lee J.M., Hoxworth J.M., Smith D., Duray P., Schumacher R.H., Yarboro C.H., Klippel J., Kleiner D., El-Gabalawy H.S. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res. 2000, 2:145-153.
178. Tchetverikov I., Lard L.R., DeGroot J., Verzijl N., Tekoppele J.M., Breedveld F.C., Huizinga T.W., Hanemaaijer R. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62:1094-1099.
179. Tchetverikov I., Ronday H.K., Van El B., Kiers G.H., Verzijl N., TeKoppele J.M., Huizinga T.W., DeGroot J., Hanemaaijer R. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63:881-883.
180. Giannelli G., Erriquez R., Iannone F., Marinosci F., Lapadula G., Antonaci S. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin. Exp. Rheumatol. 2004, 22:335-338.
181. Yamanaka H., Matsuda Y., Tanaka M., Sendo W., Nakajima H., Taniguchi A., Kamatani N. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000, 43:852-858.
182. Posthumus M.D., Limburg P.C., Westra J., van Leeuwen M.A., van Rijswijk M.H. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis. Clin. Exp. Rheumatol. 2003, 21:465-472.
183. Woolley D.E., Tetlow L.C. Observations on the microenvironmental nature of cartilage degradation in rheumatoid arthritis. Ann. Rheum. Dis. 1997, 56:151-161.
184. Brennan F.M., Browne K.A., Green P.A., Jaspar J.M., Maini R.N., Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-? (cA2) therapy. Br. J. Rheumatol. 1997, 36:643-650.
185. Vandooren B., Kruithof E., Yu D.T., Rihl M., Gu J., De Rycke L., Van Den Bosch F., Veys E.M., De Keyser F., Baeten D. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor ? blockade in spondy larthropathy. Arthritis Rheum. 2004, 50:2942-2953.
186. Amer E.C. Aggrecanase-mediated cartilage degradation. Curr. Opin. Pharmacol. 2002, 2:322-329.
187. Tortorella M.D., Burn T.C., Pratta M.A., Abbaszade I., Hollis J.M., Liu R., Rosenfeld S.A., Copeland R.A., Decicco C.P., Wynn R., Rockwell A., Yang F., Duke J.L., Solomon K., George H., Bruckner R., Nagase H., Itoh Y., Ellis D.M., Ross H., Wiswall B.H., Murphy K., Hillman M.C., Hollis G.F., Amer E.C., et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999, 284:1664-1666.
188. Hurskainen T.L., Hirohata S., Seldin M.F., Apte S.S. ADAM-TSS, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J. Biol. Chem. 1999, 274:25555-25563.
189. Abbaszade I., Liu R.Q., Yang F., Rosenfeld S.A., Ross O.H., Link J.R., Ellis D.M., Tortorella M.D., Pratta M.A., Hollis J.M., Wynn R., Duke J.L., George H.J., Hillman M.C., Murphy K., Wiswall B.H., Copeland R.A., Decicco C.P., Bruckner R., Nagase H., Itoh Y., Newton R.C., Magolda R.L., Trzaskos J.M., Burn T.C., et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J. Biol. Chem. 1999, 274:23443-23450.
190. Kuno K., Terashima Y., Matsushima K. ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. J. Biol. Chem. 1999, 274:18821-18826.
191. Kuno K., Okada Y., Kawashima H., Nakamura H., Miyasaka M., Ohno H., Matsushima K. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. 2000, 478:241-245.
192. Flannery C.R., Little C.B., Hughes C.E., Caterson B. Expression of ADAMTS homologues in articular cartilage. Biochem. Biophys. Res. Commun. 1999, 260:318-322.
193. Nagase H., Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res. Ther. 2003, 5:94-103.
194. Okada Y. Proteases and matrix degradation. Kelley's Textbook of Rheumatology 2004, 63-81. WB Saunders, Philadelphia, PA. E.D. Harris, S. Ruddy, C.B. Sledge, J.S. Sergent, R.C. Budd (Eds.).
195. Chevalier X., Groult N., Texier J.M., Larget-Piet B., Hornebeck W. Elastase activity in cartilage extracts and synovial fluids from subjects with osteoarthritis orrheumatoid arthritis: the prominent role of metalloproteinases. Clin. Exp. Rheumatol. 1996, 14:235-241.
196. Saxne T., Lecander I., Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J. Rheumatol. 1993, 20:91-96.
197. Keyszer G.M., Heer A.H., Kriegsmann J., Geiler T., Trabandt A., Keysser M., Gay R.E., Gay S. Comparative analysis of cathepsin L. cathepsin D. and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum. 1995, 38:976-984.
198. Schurigt U., Stopfel N., Huckel M., Pfirschke C., Wiederanders B., Brauer R. Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res. Ther. 2005, 7:R174-R188.
199. Taubert H., Riemann D., Kehlen A., Meye A., Bartel F., John V., Brandt J., Bache M., Wurl P., Schmidt H., Weber E. Expression of cathepsin B, D and L protein in juvenile idiopathic arthritis. Autoimmunity 2002, 35:221-224.
200. Ikeda Y., Ikata T., Mishiro T., Nakano S., Ikebe M., Yasuoka S. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J. Med. Invest. 2000, 47:61-75.
201. Hou W.S., Li Z., Gordon R.E., Chan K., Klein M.J., Levy R., Keysser M., Keyszer G., Bromme D. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol. 2001, 159:2167-2177.
202. Hou W.S., Li W., Keyszer G., Weber E., Levy R., Klein M.J., Gravallese E.M., Goldring S.R., Bromme D. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002, 46:663-674.
203. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., Foged N.T., Delmas P.D., Delaisse J.M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 1998, 273:32347-32352.
204. Elsaid K.A., Jay G.D., Chichester C.O. Detectio of collagen type II and proteoglycans in the synovial fluids of patients diagnosed with non-infectious knee joint synovitis indicates early damage to the articular cartilage matrix. Osteoarthritis Cartilage 2003, 11:673-680.
205. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., Brockbank S.M., Edwards D.R., Parker A.E., Clark I.M. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004, 50:131-141.
206. Poole A.R., Dieppe P. Biological markers in rheumatoid arthritis. Sem. Arthritis Rheum. 1994, 23:17-31.
207. Saxne T., Heinegard D. Matrix proteins: potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. J. Rheumatol. 1995, 43(Suppl.):71-74.
208. Leroux J.Y., Guerassimov A., Cartman A., Delaunay N., Webber C., Rosenberg L.C., Banerjee S., Poole A.R. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J. Clin. Invest. 1996, 97:621-632.
209. Kingsley G., Panayi G.S. Joint destruction in rheumatoid arthritis: biological bases. Clin. Exp. Rheumatol. 1997, 15:S3-S14.
210. Cremer M.A., Rosloniec E.F., Kang A.H. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J. Molec. Med. 1998, 76:275-288.
211. Cheung H.S., Ryan L.M., Kozin F., McCarty D.J. Identification of collagen subtypes in synovial fluid sediments from arthritic patients. Am. J. Med. 1980, 68:73-79.
212. Moreland L.W., Stewart T., Gay R.E., Huang G.Q., McGee N., Gay S. Immunohistologic demonstration of type II collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. Arthritis Rheum. 1989, 32:1458-1464.
213. Saxne T., Heinegard D., Wollheim F.A. Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. Relation to systemic treatment. Arthritis Rheum. 1987, 30:972-979.
214. Witter J., Roughley P.J., Webber C., Roberts N., Keystone E., Poole A.R. The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum. 1987, 30:519-529.
215. Thonar E.J., Lenz M.E., Klintworth G.K., Caterson B., Pachman L.M., Glickman P., Katz R., Huff J., Kuettner K.E. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum. 1985, 28:1367-1376.
216. Ratcliffe A., Doherty M., Maini R.N., Hardingham T.E. Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann. Rheum. Dis. 1988, 47:826-832.
217. Lohmander L.S., Dahlberg L., Ryd L., Heinegard D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 1989, 32:1434-1442.
218. Poole A.R., Witter J., Roberts N., Piccolo F., Brandt R., Paquin J., Baron M. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. Arthritis Rheum. 1990, 33:790-799.
219. Silveman B., Cawston T.E., Page Thomas D.P., Dingle J.T., Hazleman B.L. The sulphated glycosaminoglycan levels in synovial fluid aspirates in patients with acute and chronic joint disease. Br. J. Rheumatol. 1990, 29:340-344.
220. Guerassimov A., Duffy C., Zhang Y., Banerjee S., Leroux J.Y., Reimann A., Webber C., Delaunay N., Vipparti V., Ronbeck L., Cartman A., Arsenault L., Rosenberg L.C., Poole A.R. Immunity to cartilage link protein in patients with juvenile rheumatoid arthritis. J. Rheumatol. 1997, 24:959-964.
221. Guerassimov A., Zhang Y., Banerjee S., Cartman A., Leroux J.Y., Rosenberg L.C., Esdaile J., Fitzcharles M.A., Poole A.R. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthritis Rheum. 1998, 41:1019-1025.
222. Rousseau J.C., Zhu Y., Miossec P., Vignon E., Sandell L.J., Garnero P., Delmas P.D. Serum levels of type IIA procollagen amino terminal propertide (PHANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Ostearthritis Cartilage 2004, 12:440-447.
223. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Boume R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., Chen J., Van Wart H., Poole A.R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 1997, 99:1534-1545.
224. Hollander A.P., Heathfield T.F., Webber C., Iwata Y., Boume R., Rorabeck C., Poole A.R. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J. Clin. Invest. 1994, 93:1722-1732.
225. Stoop R., van der Kraan P.M., Buma P., Hollander A.P., Poole A.R., van den Berg W.B. Denaturation of type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage. J. Pathol. 1999, 188:329-337.
226. Song X., Zeng L., Jin W., Thompson J., Mizel D.E., Lei K., Billinghurst R.C., Poole A.R., Wahl S.M. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J. Exp. Med. 1999, 190:535-542.
227. Ishiguro N., Ito T., Oguchi T., Kojima T., Iwata H., Ionescu M., Poole A.R. Relationships of matrix metalloproteinases and their inhibitors to cartilage prote oglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 2001, 44:2503-2511.
228. Poole A.R., Ionescu M., Fitzcharles M.A., Billinghurst R.C. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J. Immunol. Methods. 2004, 294:145-153.
229. Kim T.H., Stone M., Payne U., Zhang X., Ionescu M., Lobanok T., King L., Poole A.R., Inman R.D. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum. 2005, 52:885-891.
230. Seibel M.J., Duncan A., Robins S.P. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J. Rheumatol. 1989, 16:964-970.
231. Astbury C., Bird H.A., McLaren A.M., Robins S.P. Urinary excretion of pyridium crosslinks of collagen correlated with joint damage in arthritis. Br. J. Rheumatol. 1994, 33:11-15.
232. Hein G., Franke S., Muller A., Braunig E., Eidner T., Stein G. The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis. Clin. Rheumatol. 1997, 16:167-172.
233. Takahashi M., Kushida K., Hoshino H., Suzuki M., Sano M., Miyamoto S., Inoue T. Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with oste oarthritis or rheumatoid arthritis. Ann. Rheum. Dis. 1996, 55:324-327.
234. Greenwald R.A. Monitoring collagen degradation in patients with arthritis. The search for suitable surrogates. Arthritis Rheum. 1996, 39:1455-1465.
235. Ronday H.K., Te Koppele J.M., Greenwald R.A., Moak S.A., De Roos J.A., Dijkmans B.A., Breedveld F.C., Verheijen J.H. Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. Br. J. Rheumatol. 1998, 37:34-38.
236. Landewe R., Geusens P., Boers M., van der Heijde D., Lems W., te Koppele J., van der Linden S., Garnero P. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum. 2004, 50:1390-1399.
237. Saxne T., Glennas A., Kvien T.K., Melby K., Heinegard D. Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum. 1993, 36:20-25.
238. Saxne T., Heinegard D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum. 1992, 35:385-390.
239. Rizkalla G., Reiner A., Bogoch E., Poole A.R. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J. Clin. Invest. 1992, 90:2268-2277.
240. Slater R.R., Bayliss M.T., Lachiewicz P.F., Visco D.M., Caterson B. Monoclonal antibodies that detect biochemical markers of arthritis in humans. Arthritis Rheum. 1995, 38:655-659.
241. Sharif M., Osborne D.J., Meadows K., Woodhouse S.M., Colvin E.M., Shepstone L., Dieppe P.A. The relevance of chondroitin and keratan sulphate markers in normal and arthritic synovial fluid. Br. J. Rheumatol. 1996, 35:951-957.
242. Bello A.E., Garrett W.E., Wang H., Lohnes J., DeLong E., Caterson B., Kraus V.B. Comparison of synovial fluid cartilage marker concentrations and chondral damage assessed arthroscopically in acute knee injury. Osteoarthritis Cartilage 1997, 5:419-426.
243. Haraoui B., Thonar E.J., Martel-Pelletier J., Goulet J.R., Raynauld J.P., Quellet M., Pelletier J.P. Serum keratan sulfate levels in rheumatoid arthritis: inverse correlation with radiographic staging. J. Rheumatol. 1994, 21:813-817.
244. Shinmei M., Miyauchi S., Machida A., Miyazaki K. Quantitation of chondroitin-4-sulfate and chondroitin-6-sulfate in pathological joint fluid. Arthritis Rheum. 1992, 35:1304-1308.
245. Belcher C., Yaqub R., Fawthrop F., Bayliss M., Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes. glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann. Rheum. Dis. 1997, 56:299-307.
246. Manicourt D.H., Poilvache P., Van Egeren A., Devogelaer J.P., Lenz M.E., Thonar E.J. Synovial fluid levels of tumor necrosis factor ? and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum. 2000, 43:281-288.
247. Lark M.W., Bayne E.K., Lohmander L.S. Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Acta Orthopaed. Scand. 1995, (Supplementum):92-97.
248. Lark M.W., Williams H., Hoernner L.A., Weidner J., Ayala J.M., Harper C.F., Christen A., Olszewski J., Konteatis Z., Webber R., et al. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum. Biochem. J. 1995, 307:245-252.
249. Fosang A.J., Last K., Gardiner P., Jackson D.C., Brown L. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem. J. 1995, 310:337-343.
250. Hughes C.E., Caterson B., Fosang A.J., Roughley P.J., Mort J.S. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem. J. 1995, 305:799-804.
251. Lark M.W., Gordy J.T., Weidner J.R., Ayala J., Kimura J.H., Williams H.R., Mumford R.A., Flannery C.R., Carlson S.S., Iwata M., et al. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the "aggrecanase" site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J. Biol. Chem. 1995, 270:2550-2556.
252. Fosang A.J., Last K., Neame P.J., Murphy G., Knauper V., Tschesche H., Hughes C.E., Caterson B., Hardingham T.E. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. Biochem. J. 1994, 304:347-351.
253. Buttner F.H., Hughes C.E., Margerie D., Lichte A., Tschesche H., Caterson B., Bartnik E. Membrane type 1 matrix metalloproteinase (MTI-MMP) cleaves the recombinant aggrecan substrate rAgglmut at the 'aggrecanase' and the MMP sites. Characterization of MTI-MMP catabolic activities on the interglobular domain of aggrecan. Biochem. J. 1998, 333:159-165.
254. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoermer L.A., Hutchinson N.I., Singer II, Donatelli S.A., Weidner J.R., Williams H.R., Mumford R.A., Lohmander L.S. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J. Clin. Invest. 1997, 100:93-106.
255. Fosang A.J., Last K., Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J. Clin. Invest. 1996, 98:2292-2299.
256. Lohmander L.S., Neame P.J., Sandy J.D. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993, 36:1214-1222.
257. Recklies A.D., Baillargeon L., White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum. 1998, 41:997-1006.
258. Dodge G.R., Hawkins D., Boesler E., Sakai L., Jimenez S.A. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts. Osteoarthritis Cartilage 1998, 6:435-440.
259. Hummel K.M., Neidhart M., Vilim V., Hauser N., Aicher W.K., Gay R.E., Gay S., Hauselmann H.J. Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluids. Br. J. Rheumatol. 1998, 37:721-728.
260. Neidhart M., Zaucke F., von Knoch R.L., Jungel A., Michel B.A., Gay R.E., Gay S. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein. Ann. Rheum. Dis. 2005, 64:419-424.
261. Forslind K., Eberhardt K., Jonsson A., Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br. J. Rheumatol. 1992, 31:593-598.
262. Joosten L.A., Helsen M.M., Saxne T., van De Loo F.A., Heinegard D., van Den Berg W.B. IL-1 ? ? blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-? blockade only ameliorates joint inflammation. J. Immunol. 1999, 163:5049-5055.
263. Roux-Lombard P., Eberhardt K., Saxne T., Dayer J.M., Wollheim F.A. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 2001, 40:544-551.
264. Larsson E., Erlandsson Harris H., Lorentzen J.C., Larsson A., Masson B., Klareskog L., Saxne T. Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats. Rheumatology (Oxford) 2002, 41:996-1000.
265. Skoumal M., Kolarz G., Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and avaluable parameter for disease management in rheumatoid arthritis. Scand. J. Rheumatol. 2003, 32:156-161.
266. Soderlin M.K., Kastbom A., Kautiainen H., Leirisalo-Repo M., Strandberg G., Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand. J. Rheumatol. 2004, 33:185-188.
267. Crnkic M., Mansson B., Larsson L., Geborek P., Heinegard D., Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res. Ther. 2003, 5:R181-R185.
268. Forsblad d'Elia H., Christgau S., Mattsson L.A., Saxne T., Ohlsson C., Nordborg E., Carlsten H. Hormone replacement therapy calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]. Arthritis Res. Ther. 2004, 6:R457-R468.
269. Hakala B.E., White C., Recklies A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 1993, 268:25803-25810.
270. Johansen J.S., Jensen H.S., Price P.A. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. 1993, 32:949-955.
271. Hu B., Trinh K., Figueira W.F., Price P.A. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J. Biol. Chem. 1996, 271:19415-19420.
272. Johansen J.S., Hvolris J., Hansen M., Backer V., Lorenzen I., Price P.A. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br. J. Rheumatol. 1996, 35:553-559.
273. Harvey S., Whaley J., Eberhardt K. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 2000, 29:391-393.
274. Volck B., Johansen J.S., Stoltenberg M., Garbarsch C., Price P.A., Ostergaard M., Ostergaard K., Lovgreen-Nielsen P., Sonne-Holm S., Lorenzen I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001, 9:203-214.
275. Vos K., Steenbakkers P., Miltenburg A.M., Bos E., van Den Heuvel M.W., van Hogezand R.A., de Vries R.R., Breedveld F.C., Boots A.M. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 2000, 59:544-548.
276. Matsumoto T., Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin. Exp. Rheumatol. 2001, 19:655-660.
277. Johansen J.S., Stoltenberg M., Hansen M., Florescu A., Horslev-Petersen K., Lorenzen I., Price P.A. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999, 38:618-626.
278. Johansen J.S., Kirwan J.R., Price P.A., Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand. J. Rheumatol. 2001, 30:297-304.
279. den Broeder A.A., Joosten L.A., Saxne T., Heinegard D., Fenner H., Miltenburg A.M., Frasa W.L., van Tits L.J., Buurman W.A., van Riel P.L., van de Putte L.B., Barrera P. Long term anti-tumour necrosis factor ? monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. 2002, 61:311-318.
280. Baeten D., Steenbakkers P.G., Rijnders A.M., Boots A.M., Veys E.M., De Keyser F. Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum. 2004, 50:444-451.
281. van Bilsen J.H., van Dongen H., Lard L.R., van der Voort E.I., Elferink D.G., Bakker A.M., Miltenburg A.M., Huizinga T.W., de Vries R.R., Toes R.E. Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 2004, 101:17180-17185.
282. De Ceuninck F., Gaufillier S., Bonnaud A., Sabatini M., Lesur C., Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem. Biophys. Res. Commun. 2001, 285:926-931.
283. Recklies A.D., White C., Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem. J. 2002, 365:119-126.
284. Ling H., Recklies A.D. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-?. Biochem. J. 2004, 380:651-659.
285. Sekine T., Masuko-Hongo K., Matsui T., Asahara H., Takigawa M., Nishioka K., Kato T. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2001, 60:49-54.
286. Knorr T., Obermayr F., Bartnik E., Zien A., Aigner T. YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is upregulated in osteoarthritic chondrocytes. Ann. Rheum. Dis. 2003, 62:995-998.
287. Saito S., Kondo S., Mishima S., Ishiguro N., Hasegawa Y., Sandell L.J., Iwata H. Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis. J. Bone Joint. Surg. Br. 2002, 84:1066-1069.
288. Goldring S.R. Bone and joint destruction in rheumatoid arthritis: what is really happening. J. Rheumatol. 2002, (Suppl. 65):44-48.
289. Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(Suppl 2):ii11-ii16.
290. Goldring S.R., Goldring M.B. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin. Orthop. Relat. Res. 2004, S27-S36.
291. Goldring M.B., Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin. Orthop. 2004, S37-S46.
292. Goldring M.B., Berenbaum F. Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression. Osteoarthritis Cartilage 1999, 7:386-388.
293. van de Loo F.A., van den Berg W.B. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum. Dis. Clin. North Am. 2002, 28:127-129.
294. Goldring M.B., Goldring S.R. Role of cytokines and chemokines in cartilage and bone destruction in arthritis. Curr. Opin. Orthopaed. 2002, 13:351-362.
295. Abramson S.B., Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002, 41:972-980.
296. Dayer J.M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003,
297. Dayer J.M. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 2004, 18:31-45.
298. Kay J., Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2004, 43(Suppl 3):iii2-iii9.
299. Lubberts E., Koenders M.I., van den Berg W.B. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 2005, 7:29-37.
300. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988, 2:706-709.
301. Rooney M., Symons J.A., Duff G.W. Interleukin 1 ? in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol. Int. 1990, 10:217-219.
302. Kahle P., Saal J.G., Schaudt K., Zacher J., Fritz P., Pawelec G. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann. Rheum. Dis. 1992, 51:731-734.
303. Houssiau F.A., Devogelaer J.P., Van Damme J., de Deuxchaisnes C.N., Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988, 31:784-788.
304. Manicourt D.H., Triki R., Fukuda K., Devogelaer J.P., Nagant de Deuxchaisnes C., Thonar E.J. Levels of circulating tumor necrosis factor ? and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum. 1993, 36:490-499.
305. Neidel J., Schulze M., Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor ? in the knee-joints of patients with rheumatoid arthritis. Inflamm. Res. 1995, 44:217-221.
306. Okamoto H., Yamamura M., Morita Y., Harada S., Makino H., Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997, 40:1096-1105.
307. Hui W., Bell M., Carroll G. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann. Rheum. Dis. 1997, 56:184-187.
308. Brennan F.M., Zachariae C.O., Chantry D., Larsen C.G., Turner M., Maini R.N., Matsushima K., Feldmann M. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur. J. Immunol. 1990, 20:2141-2144.
309. Koch A.E., Kunkel S.L., Harlow L.A., Johnson B., Evanoff H.L., Haines G.K., Burdick M.D., Pope R.M., Strieter R.M. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 1992, 90:772-779.
310. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 2000, 164:2832-2838.
311. McNearney T., Baethge B.A., Cao S., Alam R., Lisse J.R., Westlund K.N. Excitatory amino acids, TNF-?, and chemokine levels in synovial fluids of patients with active arthropathies. Clin. Exp. Immunol. 2004, 137:621-627.
312. Jouvenne P., Fossiez F., Banchereau J., Miossec P. High levels of neutralizing autoantibodies against IL-1 ? are associated with a better prognosis in chronic polyarthritis: a follow-up study. Scand. J. Immunol. 1997, 46:413-418.
313. Graudal N.A., Svenson M., Tarp U., Garred P., Jurik A.G., Bendtzen K. Autoantibodies against interleukin 1? in rheumatoid arthritis: association with longterm radiographic outcome. Ann. Rheum. Dis. 2002, 61:598-602.
314. Chikanza I.C., Roux-Lombard P., Dayer J.M., Panayi G.S. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum. 1995, 38:642-648.
315. van Roon J.A.G., Lafeber F.P.J.G., Bijlsma J.W.J. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001, 44:3-12.
316. Johansson A.C., Hansson A.S., Nandakumar K.S., Backlund J., Holmdahl R. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J. Immunol. 2001, 167:3505-3512.
317. Hata H., Sakaguchi N., Yoshitomi H., Iwakura Y., Sekikawa K., Azuma Y., Kanai C., Moriizumi E., Nomura T., Nakamura T., Sakaguchi S. Distinct contribution of IL-6, TNF-?, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 2004, 114:582-588.
318. Butrimiene I., Jarmalaite S., Ranceva J., Venalis A., Jasiuleviciute L., Zvirbliene A. Different cytokine profiles in patients with chronic and acute reactive arthritis. Rheumatology (Oxford) 2004, 43:1300-1304.
319. Loeser R.F. Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle?. Arthritis Rheum. 2003, 48:3009-3012.
320. Popa C., Netea M.G., Radstake T.R., van Riel P.L., Barrera P., van der Meer J.W. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann. Rheum. dis. 2005, 64:1195-1198.
321. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gomez-Reino J.J., Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005, 579:295-301.
322. Koch A.E. Chemokines and their receptors in rheumatoid arthritis: Future targets?. Arthritis Rheum. 2005, 52:710-721.
323. Szekanecz Z., Kim J., Koch A.E. Chemokines and chemokine receptors in rheumatoid arthritis. Semin. Immunol. 2003, 15:15-21.
324. Borzi R.M., Mazzetti I., Cattini L., Uguccioni M., Baggiolini M., Facchini A. Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum. 2000, 43:1734-1741.
325. Yuan G.H., Masuko-Hongo K., Sakata M., Tsuruha J., Onuma H., Nakamura H., Aoki H., Kato T., Nishioka K. The role of C-C chemokines and their receptors in osteoarthritis. Arthritis Rheum. 2001, 44:1056-1070.
326. Alaaeddine N., Olee T., Hashimoto S., Creighton-Achermann L., Lotz M. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum. 2001, 44:1633-1643.
327. Kanbe K., Takagishi K., Chen Q. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum. 2002, 46:130-137.
328. Morel J.C., Park C.C., Woods J.M., Koch A.E. A novel role for interleukin-18 in adhesion molecule induction through NF ? B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J. Biol. Chem. 2001, 276:37069-37075.
329. Klimiuk P.A., Sierakowski S., Latosiewicz R., Cylwik J.P., Cylwik B., Skowronski J., Chwiecko J. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann. Rheum. Dis. 2002, 61:804-809.
330. Szekanecz Z., Koch A.E. Update on synovitis. Curr. Rheumatol. Rep. 2001, 3:53-63.
331. Fearon U., Griosios K., Fraser A., Reece R., Emery P., Jones P.F., Veale D.J. Angiopoietins, growth factors, and vascular morphology in early arthritis. J. Rheumatol. 2003, 30:260-268.
332. Gudbjornsson B., Christofferson R., Larsson A. Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis. Scand. J. Clin. Lab. Invest. 2004, 64:9-15.
333. Taylor P.C. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford) 2005, 44:721-728.
334. Knudson W., Aguiar D.J., Hua Q., Knudson C.B. CD44-anchored hyaluronan-rich pericellular matrices: an ultrastructural and biochemical analysis. Exp. Cell Res. 1996, 228:216-228.
335. Loeser R.F., Carlson C.S., McGee M.P. Expression of ?1 integrins by cultured articular chondrocytes and in osteoarthritic cartilage. Exp. Cell Res. 1995, 217:248-257.
336. Brennan F.R., Mikecz K., Glant T.T., Jobanputra P., Pinder S., Bavington C., Morrison P., Nuki G. CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro. Scand. J. Immunol. 1997, 45:213-220.
337. Koller M., Aringer M., Kiener H., Erlacher L., Machold K., Eberl G., Studnicka-Benke A., Graninger W., Smolen J. Expression of adhesion molecules on synovial fluid and peripheral blood monocytes in patients with inflammatory joint disease and osteoarthritis. Ann. Rheum. Dis. 1999, 58:709-712.
338. Takagi T., Okamoto R., Suzuki K., Hayashi T., Sato M., Kurosaka N., Koshino T. Up-regulation of CD44 in rheumatoid chondrocytes. Scand. J. Rheumatol. 2001, 30:110-113.
339. Naor D., Nedvetzki S. CD44 in rheumatoid arthritis. Arthritis Res. Ther. 2003, 5:105-115.
340. Yasuda T., Poole A.R., Shimizu M., Nakagawa T., Julovi S.M., Tamamura H., Fujii N., Nakamura T. Involvement of CD44 in induction of matrix metalloproteinases by a COOH-terminal heparin-binding fragment of fibronectin in human articular cartilage in culture. Arthritis Rheum. 2003, 48:1271-1280.
341. Yasuda T., Kakinuma T., Julovi S.M., Yoshida M., Hiramitsu T., Akiyoshi M., Nakamura T. COOH-terminal heparin-binding fibronectin fragment induces nitric oxide production in rheumatoid cartilage through CD44. Rheumatology (Oxford) 2004, 43:1116-1120.
342. Mikecz K., Dennis K., Shi M., Kim J.H. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999, 42:659-668.
343. Neidhart M., Gay R.E., Gay S. Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2000, 43:1719-1728.
344. Torsteinsdottir I., Arvidson N.G., Hallgren R., Hakansson L. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc ? and complement receptor expression and the effect of glucocorticoids. Clin. Exp. Immunol. 1999, 115:554-560.
345. Firestein G.S. NF-?B: Holy Grail for rheumatoid arthritis?. Arthritis Rheum. 2004, 50:2381-2386.
346. Vincenti M.P., Brinckerhoff C.E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of genespecific transcription factors. Arthritis Res. 2002, 4:157-164.
347. Thomas B., Berenbaum F., Humbert L., Bian H., Béréziat G., Crofford L., Olivier J.L. Critical role of C/EBP? and C/EBP? factors in the stimulation of cyclooxygenase-2 gene transcription by interleukin-1? in articular chondrocytes. Eur. J. Biochem. 2000, 267:1-13.
348. Mengshol J.A., Vincenti M.P., Brinckerhoff C.E. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res. 2001, 29:4361-4372.
349. Catterall J.B., Carrere S., Koshy P.J., Degnan B.A., Shingleton W.D., Brinckerhoff C.E., Rutter J., Cawston T.E., Rowan A.D. Synergistic induction of matrix metalloproteinase 1 by interleukin-1? and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum. 2001, 44:2296-2310.
350. Liacini A., Sylvester J., Li W.Q., Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor ?B (NF-?B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002, 21:251-262.
351. Legendre F., Dudhia J., Pujol J.P., Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J. Biol. Chem. 2003, 278:2903-2912.
352. Handel M.L., McMorrow L.B., Gravallese E.M. Nuclear factor-?B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum. 1995, 38:1762-1770.
353. Grall F., Gu X., Tan L., Cho J.-Y., Inan M.S., Pettit A., Thamrongsak U., Choy B.K., Manning C., Akbarali Y., Zerbini L., Rudders S., Goldring S.R., Gravallese E.M., Oettgen P., Goldring M.B., Libermann T.A. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor ? in cells derived from rheumatoid synovium and other joint tissues involve NF ?B-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum. 2003, 48:1249-1260.
354. Redlich K., Kiener H.P., Schett G., Tohidast-Akrad M., Selzer E., Radda I., Stummvoll G.H., Steiner C.W., Groger M., Bitzan P., Zenz P., Smolen J.S., Steiner G. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor ?. Arthritis Rheum. 2001, 44:266-274.
355. Koller M., Hayer S., Redlich K., Ricci R., David J.P., Steiner G., Smolen J.S., Wagner E.F., Schett G. JNKI is not essential for TNF-mediated joint disease. Arthritis Res. Ther. 2005, 7:R166-R173.
356. Okazaki K., Li J., Yu H., Fukui N., Sandell L.J. CCA AT/Enhancer-binding proteins ? and ? mediate the repression of gene transcription of cartilage-derived retinoic acid-sensitive protein induced by interleukin-1?. J. Biol. Chem. 2002, 277:31526-31533.
357. Tan L., Peng H., Osaki M., Choy B.K., Auron P.E., Sandell L.J., Goldring M.B. Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1?. J. Biol. Chem. 2003, 278:17688-17700.
358. Imamura T., Imamura C., Iwamoto Y., Sandell L.J. Transcriptional co-activator CBP/p300 increase chondrocyte Cd-rap gene expression by multiple mechanisms including sequestration of the repressor CCAAT/enhancer-binding protein. J. Biol. Chem. 2005, 280:8343-8350.
359. Hein G.E., Kohler M., Oelzner P., Stein G., Franke S. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int. 2004, 26:137-141.
360. Foell D., Kane D., Bresnihan B., Vogl T., Nacken W., Sorg C., Fitzgerald O., Roth J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003, 42:1383-1389.
361. Martin C.A., Carsons S.E., Kowalewski R., Bernstein D., Valentino M., Santiago-Schwarz F. Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J. Immunol. 2003, 171:5736-5742.
362. Drynda S., Ringel B., Kekow M., Kuhne C., Drynda A., Glocker M.O., Thiesen H.J., Kekow J. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNF? therapy. Pathol. Res. Pract. 2004, 200:165-171.
363. Sinz A., Bantscheff M., Mikkat S., Ringel B., Drynda S., Kekow J., Thiesen H.J., Glocker M.O. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002, 23:3445-3456.
364. Hattori T., von der Mark K., Kawaki H., Yutani Y., Kubota S., Nakanishi T., Eberspaecher H., de Crombrugghe B., Takigawa M. Downregulation of rheumatoid arthritis-related antigen RA-A47 (HSP47/colligin-2) in chondrocytic cell lines induces apoptosis and cell-surface expression of RA-A47 in association with CD9. J. Cell Physiol. 2005, 202:191-204.
365. Evans C.H., Ghivizzani S.C., Herndon J.H., Wasko M.C., Reinecke J., Wehling P., Robbins P.D. Clinical trials in the gene therapy of arthritis. Clin. Orthop. 2000, S300-S307.
366. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 2001, 30(Suppl 2):17-20.
367. Feldmann M., Maini R.N. Anti-TNF ? therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
368. Dayer J.M., Bresnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum. 2002, 46:574-578.
369. Mengshol J.A., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull'seye or missing the mark?. Arthritis Rheum. 2002, 46:13-20.
370. Goldring M.B. Anticytokine therapy for osteoarthritis. Expert Opin. Biol. Ther. 2001, 1:817-829.
371. Chernajovsky Y., Vessilier S., Adams G., Gofur Y., Subang M.C., Annenkov A., Favorov P., Daly G., Gould D. Development of new molecules, vectors and cells for therapy of arthritis. Joint Bone Spine 2003, 70:474-476.
372. Vilcek J., Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 2004, 25:201-209.
373. Sweeney S.E., Firestein G.S. Signal transduction in rheumatoid arthritis. Curr. Opin. Rheumatol. 2004, 16:231-237.
374. Ishikawa T., Nishigaki F., Miyata S., Hirayama Y., Minoura K., Imanishi J., Neya M., Mizutani T., Imamura Y., Naritomi Y., Murai H., Ohkubo Y., Kagayama A., Mutoh S. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br. J. Pharmacol. 2005, 144:133-143.